Lennox-Gastaut Syndrome (LGS) Overview
Learn About Lennox-Gastaut Syndrome (LGS)
Lennox-Gastaut syndrome is a severe condition characterized by repeated seizures (epilepsy) that begin early in life. Affected individuals have multiple types of seizures, developmental delays, and particular patterns of brain activity measured by a test called an electroencephalogram (EEG). An EEG shows a slow spike-and-wave pattern during wakefulness and generalized paroxysmal fast activity during sleep.
Lennox-Gastaut syndrome can have many different causes. The disorder likely has a genetic component, although the specific genetic factors are not well understood.
Lennox-Gastaut syndrome affects an estimated 1 to 2 per million people worldwide. This condition accounts for 3 to 4 percent of cases of epilepsy in children and 1 to 2 percent of cases in adults. For unknown reasons, it appears to be more common in males than in females.
Most cases of Lennox-Gastaut syndrome are sporadic, which means they occur in people with no history of the disorder in their family. When Lennox-Gastaut syndrome is associated with a genetic change, the variant is usually not inherited but occurs as a random (de novo) event during the formation of reproductive cells (eggs or sperm) in an affected person's parent or during early embryonic development. However, 3 to 30 percent of people with this condition have a family history of some type of epilepsy, indicating that inherited genetic factors may play a role in some cases of Lennox-Gastaut syndrome.
New York University
Orrin Devinsky is a Neurologist and a General Surgeon in New York, New York. Dr. Devinsky is rated as an Elite provider by MediFind in the treatment of Lennox-Gastaut Syndrome (LGS). His top areas of expertise are Myoclonic Epilepsy, Dravet Syndrome, Seizures, Epilepsy, and Deep Brain Stimulation.
John Archer practices in Heidelberg, Australia. Mr. Archer is rated as an Elite expert by MediFind in the treatment of Lennox-Gastaut Syndrome (LGS). His top areas of expertise are Lennox-Gastaut Syndrome (LGS), Epilepsy, Seizures, Absence Seizure, and Deep Brain Stimulation.
Rima Nabbout practices in Paris, France. Ms. Nabbout is rated as an Elite expert by MediFind in the treatment of Lennox-Gastaut Syndrome (LGS). Her top areas of expertise are Myoclonic Epilepsy, Dravet Syndrome, Epilepsy with Myoclonic-Atonic Seizures, and West Syndrome.
Summary: Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).
Summary: This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult participants with Lennox-Gastaut syndrome (LGS).
Published Date: May 03, 2023
Published By: National Institutes of Health